Bausch Health Companies Inc (BHC)
6.77
-0.30
(-4.24%)
USD |
NYSE |
May 17, 16:00
6.76
-0.01
(-0.15%)
After-Hours: 20:00
Bausch Health Enterprise Value: 24.77B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 24.77B |
| May 16, 2024 | 24.88B |
| May 15, 2024 | 24.88B |
| May 14, 2024 | 24.89B |
| May 13, 2024 | 24.90B |
| May 10, 2024 | 24.81B |
| May 09, 2024 | 24.83B |
| May 08, 2024 | 24.86B |
| May 07, 2024 | 25.00B |
| May 06, 2024 | 25.04B |
| May 03, 2024 | 25.15B |
| May 02, 2024 | 25.25B |
| May 01, 2024 | 25.49B |
| April 30, 2024 | 25.50B |
| April 29, 2024 | 25.54B |
| April 26, 2024 | 25.48B |
| April 25, 2024 | 25.44B |
| April 24, 2024 | 25.42B |
| April 23, 2024 | 25.41B |
| April 22, 2024 | 25.38B |
| April 19, 2024 | 25.47B |
| April 18, 2024 | 25.44B |
| April 17, 2024 | 25.46B |
| April 16, 2024 | 25.49B |
| April 15, 2024 | 25.45B |
| Date | Value |
|---|---|
| April 12, 2024 | 25.49B |
| April 11, 2024 | 25.57B |
| April 10, 2024 | 25.55B |
| April 09, 2024 | 25.68B |
| April 08, 2024 | 25.84B |
| April 05, 2024 | 26.10B |
| April 04, 2024 | 25.97B |
| April 03, 2024 | 25.96B |
| April 02, 2024 | 26.02B |
| April 01, 2024 | 26.10B |
| March 31, 2024 | 26.17B |
| March 28, 2024 | 26.27B |
| March 27, 2024 | 26.23B |
| March 26, 2024 | 26.00B |
| March 25, 2024 | 25.86B |
| March 22, 2024 | 25.89B |
| March 21, 2024 | 25.86B |
| March 20, 2024 | 25.90B |
| March 19, 2024 | 25.88B |
| March 18, 2024 | 25.82B |
| March 15, 2024 | 25.75B |
| March 14, 2024 | 25.70B |
| March 13, 2024 | 25.77B |
| March 12, 2024 | 25.74B |
| March 11, 2024 | 25.71B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
23.16B
Minimum
May 12 2023
35.62B
Maximum
Mar 11 2021
28.70B
Average
29.71B
Median
Enterprise Value Benchmarks
| Acasti Pharma Inc | 0.1704M |
| Aurinia Pharmaceuticals Inc | 473.30M |
| Edesa Biotech Inc | 11.83M |
| Lexaria Bioscience Corp | 35.42M |
| Xenon Pharmaceuticals Inc | 2.304B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -64.00M |
| Revenue (Quarterly) | 2.153B |
| Total Expenses (Quarterly) | 1.859B |
| EPS Diluted (Quarterly) | -0.17 |
| Gross Profit Margin (Quarterly) | 70.27% |
| Profit Margin (Quarterly) | -2.97% |
| Earnings Yield | -18.32% |
| Operating Earnings Yield | 67.45% |
| Normalized Earnings Yield | -2.607 |